|
|
Recently Approved Drugs
 |
Teflaro (ceftaroline fosamil) |
 |
Company: Cerexa |
| Approval Status |
Approved November 2010 |
| Treatment Area |
Antibiotic; bacterial skin infections and bacterial pneumonia |
| General Information |
Teflaro (ceftaroline fosamil) is a novel fifth-generation cephalosporin, which exhibits broad-spectrum activity against Gram-positive bacteria, including MRSA and extensively-resistant strains. |
 |
Dificid (fidaxomicin) |
 |
Company: Optimer Pharmaceuticals |
| Approval Status |
Approved May 2011 |
| Treatment Area |
Antibiotic; Clostridium difficile-associated diarrhea |
| General Information |
Dificid (fidaxomicin) is a narrow-spectrum macrocyclic antibiotic, specifically indicated for Clostridium difficile-associated diarrhea in adults. |
| |
Belviq (lorcaserin hydrochloride) |
 |
Company: Arena Pharmaceuticals |
| Approval Status |
Approved June 2012 |
| Treatment Area |
Weight loss management |
| General Information |
Belviq (lorcaserin hydrochloride) is a serotonin 2C receptor agonist. It has been shown to decrease food consumption and promote satiety by selectively activating serotonin 2C receptors in the brain. |
 |
Stendra (avanafil) |
 |
Company: Vivus |
| Approval Status |
Approved April 2012 |
| Treatment Area |
Erectile dysfunction |
| General Information |
Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. |
 |
Viibryd (vilazodone hydrochloride) |
 |
Company: Forex Laboratories |
| Approval Status |
Approved January 2011 |
| Treatment Area |
Major depressive disorder |
| General Information |
Viibryd (vilazodone hydrochloride) is a serotonergic antidepressant (a selective serotonin reuptake inhibitor and a 5HT1A receptor partial agonist) developed for the treatment of major depressive disorder. |
 |
Vascepa (icosapent ethyl) |
 |
Company: Amarin Pharmaceuticals |
| Approval Status |
Approved July 2012 |
| Treatment Area |
Cholesterol lowring drug; Hypertriglyceridemia |
| General Information |
Vascepa is indicated for the treatment of very high levels of triglycerides. It contains ultra-purified ethyl EPA, an omega-3 fatty acid. Vascepa is the second prescription fish oil formulation, following GlaxoSmithKline‘s Lovaza. |
 |
Livalo (pitavastatin) |
 |
Company: Kowa Company |
| Approval Status |
Approved August 2009 |
| Treatment Area |
Cholesterol lowring drug; Primary hyperlipidemia and mixed dyslipidemia |
| General Information |
Livalo (pitavastatin) is a highly potent novel synthetic statin engineered in Japan. |
|
|
